For many women, breast cancer screening with a three-dimensional imaging technique called digital breast tomosynthesis (DBT) may not offer advantages over digital mammography, but for some it may reduce the chance of an advanced cancer diagnosis, according to a new JAMA study.
UCSF research scientists and statisticians have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients. The new cancer response subtypes reflect responsiveness to drug treatments and are intended to help clinicians be more precise in how they target therapies.
Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.
What kills most people who die from cancer is not the initial tumor. It’s the intolerable disease burden on the body that arises when tumor cells continually expand their numbers after spreading to different organs.
A new model of the causes of breast cancer, created by a team led by researchers at UCSF, Genentech and Stanford University, is designed to capture the complex interrelationships between dozens of primary and secondary breast cancer causes and stimulate further research.
In a breakthrough with important implications for the future of immunotherapy for breast cancer, UCSF scientists have found that blocking the activity of a single enzyme can prevent a common type of breast cancer from spreading to distant organs.
A new web tool spells out for the first time the exposures that more than 6.5 million working women in California face that could increase their risk for breast cancer, including industrial solvents, antimicrobials and phthalates.
Researchers identified a protein that cancer cells use as a shield to protect the PI3K pathway against targeted drugs, and showed that blocking this protein allowed previously ineffective therapies to slow cancer cell growth and shrink tumors.
UCSF: The Campaign is taking on the world’s most complex health challenges, powered by an exceptional community of mavericks, innovators, and advocates. Together we will make the Bay Area and our world healthier for all.
A molecular test can pinpoint which patients will have a very low risk of death from breast cancer even 20 years after diagnosis and tumor removal, according to a new clinical study led by UCSF in collaboration with colleagues in Sweden.